|Amgen Inc -- USA Stock|| |
USD 183.55 0.05 0.0272%
Dr. David Baltimore, Ph.D., is an Independent Director of Amgen Inc. David Baltimore is President Emeritus and Robert Andrews Millikan Professor of Biology at the California Institute of Technology, or Caltech. He received the Nobel Prize in Medicine as a corecipient in 1975. Dr. Baltimore was a director of Regulus Therapeutics Inc., a biopharmaceutical company, since 2007, serving on its Compensation Committee and chairing its Nominating and Governance Committee, and is a member of its scientific advisory board
Age: 78 Director Since 1999 Ph.D
Baltimore has also been a member of the board of directors of Immune Design Corporationrationration, a clinicalstage immunotherapy company, since 2008, chairing its Nominating and Governance Committee, and is a member of its scientific advisory board. He was a director of BB Biotech, AG, a Swiss investment company, from 1994 to March 2011 and served as a director of MedImmune, Inc., a privatelyheld antibody formulation company, from 2003 until its acquisition by AstraZeneca plc, a pharmaceutical and biotechnology company, in 2007. In 2008, Dr. Baltimore became a founder of Calimmune, Inc., a privatelyheld clinicalstage gene therapy company, and served as Chairman of the board of directors until November 2015.
David Baltimore Latest Insider Activity
The company has return on total asset (ROA)
of 8.32 %
which means that it generated profit of $8.32 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of 7.18 %
meaning that it created $7.18 on every $100 dollars invested by stockholders.
The company currently holds 35.34 B in liabilities with Debt to Equity (D/E) ratio of 140.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 5.38 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 20800 people.Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.